Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent
References (57)
- et al.
Inhibition of transplantable melanoma tumor development in mice by prophylactic administration of Ca-ascorbate
Life Sciences
(1983) Protocol for the use of vitamin C in the treatment of cancer
Med Hypotheses
(1991)- et al.
The orthomolecular treatment of cancer. 1. The role of ascorbate in host resistance
Chem Biol Interact
(1974) - et al.
The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer
Chem Biol Interact
(1974) - et al.
The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy
Chem Biol Interact
(1975) - et al.
Innovation vs quality control: an ‘unpublishable’ clinical trial of supplemental ascorbate in incurable cancer
Med Hypotheses
(1991) Vitamin C: the nontoxic, nonrate-limited, antioxidant free radical scavenger
Med Hypotheses
(1985)Guest editorial: evolution of chemotherapy
CA Cancer J Clin
(1991)Cancer chemotherapeutic and biologic agents
CA Cancer J Clin
(1991)- et al.
Cancer statistics 1994
CA Cancer J Clin
(1994)
Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-I, 2, 4triazole
Oncology
Vitamin C preferential toxicity for malignant melanoma cells
Nature
Effects of sodium ascorbate (vitamin C) and 2-methyl-1, 4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro
Cancer
Characterization of a new malignant human T -cell line (PFI-285) sensitive to ascorbic acid
Eur J Haematol
Growth suppression of human leukemic cells in vitro by L-ascorbic acid
Cancer Res
Anti-tumor potency of ascorbic, dehydroascorbic, or 2,3-diketogulonic acid and their action on deoxyribonucleic acid
Z Krebsforsch
Effects of tetraacetyl-bis-dehydroAA, a derivative of ascorbic acid, on Ehrlich cells and HeLa cells (human carcinoma cells)
J Nutr Sci Vitaminol
Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells
J Cell Physiol
Cure of advanced Lewis lung carcinoma (LL): a new treatment strategy
Vitamin C inhibits DNA, RNA and protein synthesis in epithelial neoplastic cells
Intl J Vit Nutr Res
Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B-16 melanoma
Cancer Res
Effects of ascorbic acid on survival and cell-mediated immunity in tumor bearing mice
IRCS Med Sci
In vivo antineoplastic activity of ascorbic acid for human mammary tumor
In vivo
Ascorbic acid and cancer: a review
Cancer Res
Vitamin C and immune functions: mechanisms of immunostimulation
Ascorbic acid: biologic functions and relation to cancer: commentary
JNCI
Cited by (107)
Starving Cancer Cells: Evidence-Based Strategies to Slow Cancer Progression: A Selection of Readings for Health Services Providers
2021, Starving Cancer Cells: Evidence-Based Strategies to Slow Cancer Progression A Selection of Readings for Health Services ProvidersO<inf>2</inf><sup>⋅−</sup> and H<inf>2</inf>O<inf>2</inf>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
2017, Cancer CellCitation Excerpt :Intravenous pharmacological doses of ascorbate have recently re-emerged as a potential anti-cancer therapy with clinical trials in ovarian and pancreatic cancer subjects demonstrating tolerability with similar or reduced toxicities, relative to chemotherapy alone (Ma et al., 2014; Monti et al., 2012; Welsh et al., 2013). Preclinical studies with ascorbate have consistently demonstrated cancer cell-selective cytotoxicity in a variety of disease sites (Du et al., 2010; Ma et al., 2014; Riordan et al., 1995). Although the mechanism(s) of selective toxicity remain unknown, mounting evidence suggests that ascorbate toxicity is dependent on the action of ascorbate as a pro-drug for hydrogen peroxide (H2O2) generation (Chen et al., 2005, 2007; Olney et al., 2013).
Liposome-based drug co-delivery systems in cancer cells
2017, Materials Science and Engineering CCitation Excerpt :Vitamin C is a strong reducing agent that plays a role in various physiological functions [73–75]. Vitamin C not only displays cytotoxicity toward cancer cells but also improves the anti-neoplastic effect of some anti-cancer agents, in particular anthracyclines, because one of their cytotoxic effects is related to free radical production [76–80]. It was revealed that DOX and vitamin C have synergistic activity toward the breast carcinoma cells over a wide range of vitamin C concentrations [81].
Non-coding RNA/microRNA-modulatory dietary factors and natural products for improved cancer therapy and prevention: Alkaloids, organosulfur compounds, aliphatic carboxylic acids and water-soluble vitamins
2016, Non-coding RNA ResearchCitation Excerpt :A clinical study of the Mayo Clinic used only oral vitamin C and, thus, could not reproduce the promising results of Cameron and coworkers which underlines the high importance of intravenous application of vitamin C in order to reach sufficient blood plasm concentrations of vitamin C (up to 5.5 mmol/L after 10 g vitamin C, i.v.; up to 13.5 mmol/L after 50 g vitamin C, i.v.) [156–158]. Several newer cancer case studies and trials that applied high-dose vitamin C infusions reported of significant tumor remission and reduced side-effects when combined with chemotherapeutic agents (e.g., paclitaxel) [159–164]. A phase I clinical trial of the combination of vitamin C and gemcitabine in metastatic pancreatic cancer patients (PACMAN study) revealed a mean survival time of 13 months, which was more than twice of the mean survival time of patients treated only with gemcitabine (5.65 months) [164,165].
Microbial influences on hormesis, oncogenesis, and therapy: A review of the literature
2015, Environmental ResearchCitation Excerpt :Watson stated that antioxidants cause cancer, interferes with its treatments (which would make sense since many of the treatments induce higher concentrations of ROS), and that antioxidants actually promote the growth of late stage metastatic cancer (Watson, 2013). However, it could actually be the fact that some antioxidants such as vitamin C will act as pro-oxidants as well, depending on their environment (Casciari et al., 2001; Riordan et al., 1995). If that is the case than bacteria could be the key delivery method to producing lipopolysaccharides in the body that will both act as an antioxidant in healthy tissues while acting as a pro-oxidant in neoplasms.